A multicenter telephone-interview study has found that cancer patients often perceive that communication problems with healthcare providers have contributed to a breakdown in their care, but very few formally report their concerns.
Earlier today the FDA approved pazopanib (Votrient) to treat patients with advanced soft-tissue sarcoma who have previously received chemotherapy. More than 20 subtypes of sarcoma were included in the clinical trial that led to the approval.
Results from a phase II clinical trial with HSPPC-96 (vitespen), an autologous heat shock protein-peptide vaccine, have shown promise in patients with recurrent glioblastoma multiforme.
Researchers from the United Kingdom and Canada have released new data genetically characterizing over 2,000 breast tumors. The work provides a framework to understand how gene copy-number aberrations affect gene expression in breast cancer and reveals novel subgroups that could be targets of future investigations.
Though the calcium-dependent chloride channel DOG1 is strongly expressed in gastrointestinal stromal tumors (GIST), a new laboratory study suggests that methods targeting it for therapies in treating these cancers are still a ways off.
Researchers at the Mayo Clinic in Rochester, Minnesota, found an eight-fold increase in melanoma incidence among young women between 1970 and 2009 in an epidemiological study. The increase was not as striking among young men, but there was still a four-fold jump in melanoma cases over those four decades.
The presence of a mutation in the MEK1 gene in melanoma patients does not cause resistance to BRAF inhibitor therapy in patients that also carry a BRAF mutation, according to a new study. Previously, experts believed that resistance to the drugs in BRAF-mutated melanoma patients could likely be blamed on the concurrent mutation in MEK1.
A study published today details a scoring system that may predict which ovarian cancer patients responded to first-line platinum chemotherapy based on a DNA-repair pathway-focused score. The score is based on a gene expression profile of 23 DNA-repair genes that normally function to repair platinum-induced DNA damage.
A large-scale study of US women between the ages of 20 and 44 shows that using the injectable contraceptive, depot medroxyprogesterone acetate (DMPA), is associated with a two-fold increase in the risk of invasive breast cancer when the contraceptive is used for at least one year.
Scientists in Germany have potentially found a way to indirectly target the MYC oncogene—an elusive cancer therapy target to date, discovering that cancer cells with upregulated levels of MYC are dependent on AMPK-related kinase 5 to stay alive. Inhibition of ARK5 causes these MYC-dependent cells to die.